Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > REGULATORY
REGULATORY
- PFSB Issues Notification on Package Inserts of Regenerative Medicine Products
October 14, 2014
- PFSB Announces New Format for ADR Reporting to Be Used Starting in FY2016
October 14, 2014
- MOF Panel to Pitch Reference Pricing for Long-Listed Drugs, Price Cut in FY2015
October 9, 2014
- PMDA Begins Accepting Applications for Regulatory Review Schedule Meetings
October 9, 2014
- Chuikyo to Discuss Handling of Regenerative Medicine Products Under Health Insurance Programs
October 9, 2014
- MHLW to Add Page to Website in FY2016 to Help Hospitals, Pharmacies Select Generic Drug Makers
October 8, 2014
- Minister Calls on Hospitals, Pharmacies to Report Price Settlement Rates within October
October 8, 2014
- Editor’s Pick: Five Healthcare News Headlines for Sept. 22 - Oct. 3
October 6, 2014
- MEXT Redefines Objective of Generic Promotion Subsidy Project to Continue Funding in FY2015
October 6, 2014
- MHLW Panel Agrees that Legal Regulation of Clinical Research Would Be “Difficult”
October 3, 2014
- Govt Panel Calls for Fact-Finding Study for Annual NHI Price Revision
October 3, 2014
- MHLW Issues Guidelines on Package Insert Updates Mandated under Revised PAL
October 2, 2014
- MHLW Issues Warning on ARB, ACE Inhibitors in Pregnant Women
October 1, 2014
- PMDA Evaluating Xtandi for Risk of Thrombocytopenia
September 30, 2014
- MHLW OKs 19 Products Including MSD’s Insomnia Drug Suvorexant
September 29, 2014
- Daclatasvir/Asunaprevir Combination Therapy for Hepatitis C Now Eligible for Medical Subsidy: MHLW
September 26, 2014
- Govt Panel Approves Plan for Special Zone in Kansai Area Where Mixed-Healthcare Using Unapproved Drugs Will Be Permitted
September 26, 2014
- Editor’s Pick: Five Healthcare News Headlines for September 8 – September 19
September 25, 2014
- Copayment Hike for New Drugs Up for Discussion towards Healthcare Overhaul
September 25, 2014
- MHLW Approves Additional Indications for Aricept, 2 Other Drugs
September 22, 2014
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…